SML3115
L-690,330
≥98% (HPLC)
别名:
L 690330, L-690330, P,P′-[1-(4-Hydroxyphenoxy)ethylidene]bis[phosphonic acid], [1-(4-Hydroxyphenoxy)ethylidene]bisphosphonic acid
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C8H12O8P2
化学文摘社编号:
分子量:
298.12
UNSPSC Code:
12352107
NACRES:
NA.77
MDL number:
InChI
1S/C8H12O8P2/c1-8(17(10,11)12,18(13,14)15)16-7-4-2-6(9)3-5-7/h2-5,9H,1H3,(H2,10,11,12)(H2,13,14,15)
SMILES string
OC1=CC=C(OC(C)(P(O)(O)=O)P(O)(O)=O)C=C1
InChI key
JKOCAAWWDVHWKB-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
H2O: 2 mg/mL, clear
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
L-690,330 is potent and selective competitive inhibitor of inositol inositol monophosphatase (IMPase), which is stable to hydrolysis. Recently L-690,330 used to activate autophagy and protect against alpha-synuclein-induced toxicity in Lund human mesencephalic (LUHMES) neurons without influencing dopaminergic markers.
Potent and selective competitive inhibitor of inositol monophosphatase; which is stable to hydrolysis; Induces autophagy
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
J R Atack et al.
The Journal of pharmacology and experimental therapeutics, 270(1), 70-76 (1994-07-01)
In order to enhance the entry into cells of L-690,330, a bisphosphonate inhibitor of inositol monophosphatase (IMPase; a key, enzyme in the phosphatidylinositol (Pl) cell signaling pathway), the tetrapivaloyloxymethyl ester prodrug, L-690,488 [tetrapivaloyloxymethyl 1-(4-hydroxyphenoxy)ethane-1,1-bisphosphonate], was synthesized. The effects of L-690,488
I Antoniadou et al.
British journal of pharmacology, 175(13), 2599-2610 (2018-03-01)
Lithium's antidepressant action may be mediated by inhibition of inositol monophosphatase (IMPase), a key enzyme in Gq -protein coupled receptor signalling. Recently, the antioxidant agent ebselen was identified as an IMPase inhibitor. Here, we investigated both ebselen and lithium in
Matthias Höllerhage et al.
Neuropharmacology, 149, 13-26 (2019-02-08)
Pathological aggregates of alpha-synuclein are the common hallmarks of synucleinopathies, including Parkinson's disease. There is currently no disease-modifying therapy approved for neurodegenerative synucleinopathies. The induction of macroautophagy by small compounds may be a strategy to reduce the cellular alpha-synuclein burden
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持